Toggle Main Menu Toggle Search

Open Access padlockePrints

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia

Lookup NU author(s): Professor Anthony MoormanORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

The Philadelphia chromosome positive arm of the UKALLXII/ECOG2993 study for adult acute lymphoblastic leukemia (ALL) enrolled 266 patients between 1993 and 2003 (preimatinib cohort). In 2003 imatinib was introduced as a single-agent course following induction (N = 86, late imatinib). In 2005 imatinib was added to the second phase of induction (N = 89, early imatinib). The complete remission (CR) rate was 92% in the imatinib cohort vs 82% in the preimatinib cohort (P = .004). At 4 years, the overall survival (OS) of all patients in the imatinib cohort was 38% vs 22% in the preimatinib cohort (P = .003). The magnitude of the difference between the preimatinib and imatinib cohorts in event-free survival (EFS), OS, and relapse-free survival (RFS) seen in univariate analysis was even greater in the multivariate analysis. In the preimatinib cohort, 31% of those starting treatment achieved hematopoietic stem cell transplant (alloHSCT) compared with 46% in the imatinib cohort. A Cox multivariate analysis taking alloHSCT into account showed a modest additional benefit to imatinib (hazard ratio for EFS = 0.64, 95% confidence interval 0.44-0.93, P = .02), but no significant benefit for OS and RFS. Adding imatinib to standard therapy improves CR rate and long-term OS for adults with ALL. A proportion of the OS benefit derives from the fact that imatinib facilitates alloHSCT. This trial was registered at clinicaltrials.gov as NCT00002514.


Publication metadata

Author(s): Fielding AK, Rowe JM, Buck G, Foroni L, Gerrard G, Litzow MR, Lazarus H, Luger SM, Marks DI, McMillan AK, Moorman AV, Patel B, Paietta E, Tallman MS, Goldstone AH

Publication type: Article

Publication status: Published

Journal: Blood

Year: 2014

Volume: 123

Issue: 6

Pages: 843-850

Print publication date: 06/02/2014

ISSN (print): 0006-4971

ISSN (electronic): 1528-0020

Publisher: American Society of Hematology

URL: http://dx.doi.org/10.1182/blood-2013-09-529008

DOI: 10.1182/blood-2013-09-529008


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
Leukaemia and Lymphoma Research UK, in the UK
Medical Research Council (UK)
CA13650Leukaemia and Lymphoma Research, In the US
CA15488Leukaemia and Lymphoma Research, In the US
CA14548Leukaemia and Lymphoma Research, In the US
CA14958Leukaemia and Lymphoma Research, In the US
CA17145Leukaemia and Lymphoma Research, In the US
CA21115Leukaemia and Lymphoma Research, In the US

Share